Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Gastrointestinal Neoplasms, Esophagogastric Junction

In brief

This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN).

Key facts

Study ID
NCT04592913
Run by
AstraZeneca
People needed
957
Starts
2020-11-17
Expected to finish
2027-09-27
Last updated by the study team
2025-12-24

Who can join

Age: 18 and older, up to 200. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.